Extending provision of cell-free (cf)DNA screening for Down syndrome.

Extending provision of cell-free (cf)DNA screening for Down syndrome. BJOG. 2020 Sep 05;: Authors: Cuckle HS Abstract It is now 12 years since the discovery that fetal cfDNA fragments in maternal plasma can be used to detect Down syndrome. This single marker has a detection rate above 99% and a false-positive rate below 0.2%, a performance greatly exceeding conventional multiple serum and ultrasound marker screening tests. Nevertheless, there has not been widespread replacement of conventional screening by cfDNA. Commercial providers report annual cfDNA testing totaling millions but this covers only a few percent of pregnancies worldwide. PMID: 32892448 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research